Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 8
Submit an article Journal homepage
2,427
Views
2
CrossRef citations to date
0
Altmetric
Editorial

The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future

Mark A. SamaanGuy’s and St Thomas’ NHS Foundation Trust, IBD Centre, Department of Gastroenterology, North Wing, St Thomas’ Hospital, London, United Kingdom
&
Peter M. IrvingGuy’s and St Thomas’ NHS Foundation Trust, IBD Centre, Department of Gastroenterology, North Wing, St Thomas’ Hospital, London, United KingdomCorrespondence[email protected]
Pages 975-977 | Received 11 Apr 2016, Accepted 10 May 2016, Published online: 31 May 2016

References

  • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462–2476. PubMed PMID: 16339095.
  • Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780–787. PubMed PMID: 21209123.
  • Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257–65e1-3. PubMed PMID: 22062358.
  • Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):85–95. PubMed PMID: 23735746.
  • Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96–109e1. PubMed PMID: 23770005.
  • Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710. PubMed PMID: 23964932.
  • Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug;135(2):400–409. PubMed PMID: 18602921.
  • Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr;102(4):794–802. PubMed PMID: 17324131.
  • Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012 Dec;6(10):991–1030. PubMed PMID: 23040451.
  • Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004 Feb;126(2):402–413. PubMed PMID: 14762776.
  • Panccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology. 2011 May;140(5(suppl 1)):S–134.
  • Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003 Jul;52(7):998–1002. PubMed PMID: 12801957. Pubmed Central PMCID: 1773722.
  • Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and −2 extension studies. Inflamm Bowel Dis. 2012 Feb;18(2):201–211. PubMed PMID: 21484965.
  • Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014 Feb;49(2):283–294. PubMed PMID: 24363029. Pubmed Central PMCID: 3925299.
  • Kennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016 Feb 19. doi:10.1111/apt.13547. PubMed PMID: 26892328. Pubmed Central PMCID: 4793922.
  • Blackmore L, Harris A. A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn’s disease: how will NICE guidance affect patient care? Clin Med. 2012 Jun;12(3):235–238. PubMed PMID: 22783774.
  • Salleron J, Danese S, D’Agay L, et al. Effectiveness research in inflammatory bowel disease: a necessity and a methodological challenge. J Crohns Colitis. 2016 Mar 3. pii: jjw068. [Epub ahead of print]. PMID 26944416.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.